Lumida
/WELL
⌘K
Welltower Inc

Welltower Inc

WELL
$243.25USD+0.73%+1.76 today

MARKET CAP

171.7B

P/E (TTM)

120.4x

FWD P/E

78.3x

DAY RANGE

$242 – $246

52W RANGE

$156
$246

AI Summary

Stalk
StalkMedium

WELL remains in a strong Stage 2 advancing uptrend with sustained medium-term bullish momentum, but price is currently extended above rising EMAs and extreme overbought conditions caution against immediate entry. We defer execution and await a pullback into the confluence of the 9 and 21 EMA and prior support zone to confirm acceptance before buying.

  • Q1 revenue rose 25% YoY to $368M; MRR up 38% to $6.4M
  • 2026 guidance targets 11–18% revenue growth toward ~$800M and $100M+ adj EBITDA
  • Adjusted FCF fell to $1.6M from $11.8M, reflecting cash strain
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Well Health Technologies Corp. (TSX: WELL) operates as a prominent provider in the Canadian healthcare sector, focusing on delivering a fully integrated healthcare platform combining digital health solutions and clinic operations. The company has established itself within the growing trend of tech-enabled healthcare, leveraging advanced technologies like artificial intelligence to enhance patient care and operational efficiency. Well Health is positioned to capitalize on the rising demand for personalized, accessible healthcare, especially as the aging population increases the need for integrated care solutions.

Bull says

  • Q1 revenue rose 25% YoY to $368M; MRR up 38% to $6.4M
  • 2026 guidance targets 11–18% revenue growth toward ~$800M and $100M+ adj EBITDA
  • AI-powered WellSTAR integration boosts operating leverage and patient outcomes
  • High momentum and low volatility factor profile supports stable upside
  • Aggressive M&A strategy adds scale; 19 deals closed in 2025, 40+ targets engaged

Bear says

  • Adjusted FCF fell to $1.6M from $11.8M, reflecting cash strain
  • CapEx surged 88% YoY, pressuring free cash flow and margins
  • Regulatory billing inquiry in the US could disrupt revenue recognition
  • Negative profitability factor and weak earnings yield limit returns
  • Intensifying healthcare-tech competition threatens market share
  • Downward analyst revisions reflect lowered growth expectations

Investment themes with WELL

Nuclear +1.23%

Nuclear energy production and related companies

WELL · PLD · EQIX
Demographics: Elderly Care -0.26%

Services and products for aging population

UCB.BR · JNJ · AZN
Residential REITs +0.00%

Stable income from diversified rental housing portfolios

WELL · PSA · VTR

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 06-04-2026neutral

Transcript signals

Bull points

  • Well achieved record quarterly revenue of $231.2 million in Q4 2023, an increase of 48% as compared to revenue of $156.5 million generated during Q4 2022. This growth was driven by acquisitions and organic growth.
  • Well-achieved record adjusted gross profit of 101 million in Q4 2023, an increase of 26% as compared to adjusted gross profit of 80.2 million in Q4 2022. Growth in the company's adjusted gross profit is attributable to higher revenue in the period.
  • Adjusted free cash flow was $12.7 million in Q4 2023, an increase of 23% as compared to adjusted free cash flow of $10.3 million in Q4 2022. This was mainly due to higher EBITDA generation.

Bear points

  • Adjusted net income was 52.4 million or 22 cents per share in 2023, a decrease of 2% as compared to adjusted net income of 53.7 million or 24 cents per share in 2022.
  • Adjusted free cash flow was $42.4 million for 2023, a decrease of 13% as compared to adjusted free cash flow of $48.9 million for 2022. The decrease was mainly due to higher tax and interest payments, offsetting the increase in shareholder EBITDA.
  • Net income was $16.6 million or zero cents per share in 2023, a decrease of 11%, as compared to net income of $18.7 million or $0 per share in 2022.
Read full transcript analysis ›